Compounds > cefaclor
Page last updated: 2024-11-06

cefaclor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cefaclor is a second-generation cephalosporin antibiotic. It is synthesized through a series of chemical reactions that involve the modification of the cephalosporin nucleus. Cefaclor is primarily used to treat bacterial infections, including respiratory infections, urinary tract infections, and skin infections. It works by inhibiting the synthesis of bacterial cell walls. It is an important antibiotic because it is effective against a wide range of bacteria and is generally well-tolerated. Cefaclor is studied to investigate its efficacy and safety in treating various infections and to explore its potential for developing new antibiotics with improved properties.'

Cross-References

ID SourceID
PubMed CID51038
CHEMBL ID1201018
SCHEMBL ID33539
MeSH IDM0003713

Synonyms (71)

Synonym
raniclor
PRESTWICK_783
ceclor
70356-03-5
cefaclor (usp)
ceclor (tn)
D02352
cefaclor monohydrate
alfatil kapseln
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, monohydrate, (6r-(6alpha,7beta(r*)))-
compound 99638
cefaclor-1-wasser
cefaclor hydrate
kefolor suspension
lilly 99638 hydrate
panacef
3-chloro-7-d-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate
muco panoral
kefolor
(6r,7r)-7-((r)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate
alfatil
distaclor
compound-99638
CHEMBL1201018
nsc-757422
j01dc04
HMS1569B11
(6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
A836854
7-[(2-amino-2-phenyl-acetyl)amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate;cefaclor monohydrate
HMS2096B11
cefaclor [usan:usp:inn:ban:jan]
69k7k19h4l ,
unii-69k7k19h4l
nsc 757422
AKOS016010170
cefaclor, monohydrate
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, monohydrate, (6r-(6.alpha.,7.beta.(r*)))-
cefaclor monohydrate [vandf]
cefaclor [vandf]
cefaclor monohydrate [who-dd]
cefaclor [usan]
cefaclor [ep monograph]
cefaclor [orange book]
cefaclor monohydrate [mi]
(6r,7r)-7-[(r)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate
cefaclor [usp-rs]
cefaclor [mart.]
cefaclor [usp monograph]
S1499
keflor
CCG-220485
SCHEMBL33539
cefachlor
cefaclor monohydrate; (6r,7r)-7-[[(2r)-aminophenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate; 7-(d-2-amino-2-phenylacetamido)-3-chloro-3-cephem-4-carboxylic acid monohydrate
sr-01000000152
SR-01000000152-4
(6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
HMS3713B11
(6r,7r)-7-((r)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
HY-B0198A
cefaclor (monohydrate)
mfcd00071999
DTXSID80990551
7-[(2-amino-1-hydroxy-2-phenylethylidene)amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid--water (1/1)
WKJGTOYAEQDNIA-IOOZKYRYSA-N
C76242
CS-0013096
(6r,7r)-7-[(2r)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
AS-57307
70356-03-5 (hydrate)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID94130Minimum inhibitory concentration (MIC) against Klebsiella pneumoniae by 2-fold microdilution technique.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID198183Minimum inhibitory concentration (MIC) against Streptococcus pneumoniae by 2-fold microdilution technique1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID25254Pseudo-first-order Rate constant for hydrolysis at pH 101988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones.
AID198313Minimum inhibitory concentration (MIC) against Streptococcus pyogenes by 2-fold microdilution technique1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID69505Minimum inhibitory concentration was measured against Escherichia coli EC141991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID198310Minimum inhibitory concentration against Streptococcus pyogenes1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 3. Synthesis and biological properties of 7 alpha-methoxy-7 beta-(arylacetamido)-3-chloro-3-cephem-4- carboxylic acids.
AID209734Minimum inhibitory concentration was measured against streptococcus pneumonia PARK1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID200262Minimum inhibitory concentration (MIC) against Staphylococcus aureus by 2-fold microdilution technique.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID200346Minimum inhibitory concentration was measured against salmonella 11351991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID79398Minimum inhibitory concentration (MIC) against Haemophilus influenzae by 2-fold microdilution technique.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID200261Minimum inhibitory concentration against Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 3. Synthesis and biological properties of 7 alpha-methoxy-7 beta-(arylacetamido)-3-chloro-3-cephem-4- carboxylic acids.
AID198019Minimum inhibitory concentration (MIC) against Streptococcus faecalis by 2-fold microdilution technique.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID151367Minimum inhibitory concentration (MIC) against Proteus mirabilis by 2-fold microdilution technique.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID85801Minimum inhibitory concentration against H influenzae(beta-lactamase (-))1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 3. Synthesis and biological properties of 7 alpha-methoxy-7 beta-(arylacetamido)-3-chloro-3-cephem-4- carboxylic acids.
AID205900Minimum inhibitory concentration was measured against staphylococcus epidermidis 2221991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID200347Minimum inhibitory concentration was measured against salmonella X5141991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID64069Minimum inhibitory concentration (MIC) against Escherichia coli by 2-fold microdilution technique.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
An examination of O-2-isocephems as orally absorbable antibiotics.
AID85803Minimum inhibitory concentration against Haemophilus influenzae (beta-lactamase (+))1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 3. Synthesis and biological properties of 7 alpha-methoxy-7 beta-(arylacetamido)-3-chloro-3-cephem-4- carboxylic acids.
AID202094Minimum inhibitory concentration against Streptococcus pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 3. Synthesis and biological properties of 7 alpha-methoxy-7 beta-(arylacetamido)-3-chloro-3-cephem-4- carboxylic acids.
AID164052Minimum inhibitory concentration was measured against Pseudomonas X5281991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID64068Minimum inhibitory concentration against Escherichia coli1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 3. Synthesis and biological properties of 7 alpha-methoxy-7 beta-(arylacetamido)-3-chloro-3-cephem-4- carboxylic acids.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 105.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index105.18 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index184.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (105.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial [NCT05925309]356 participants (Anticipated)Interventional2023-07-01Recruiting
Postoperative Healthcare Utilization in Adenotonsillectomy Patients With Postoperative Antibiotic Administration Compared to Patients Without Antibiotic Administration [NCT01561703]58 participants (Actual)Interventional2012-03-31Completed
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis [NCT05398679]Phase 4360 participants (Anticipated)Interventional2022-06-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01561703 (1) [back to overview]Healthcare Utilization

Healthcare Utilization

Questionnaire designed to evaluate healthcare utilization following surgery. Unit of measure will be the number of participants utilizing each category of healthcare. (NCT01561703)
Timeframe: 6 wks post-operative appointment

,
Interventionparticipants (Number)
Reported FeverMade a phone call to clinicER/UR/Clinic visit"Received additional antibiotic"Diagnostic workup at ER
Control168966
Intervention55200

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cephalothin
Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.		1.9710azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
penicillin v
Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.		1.9710penicillin allergen;
penicillin
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		2.3720beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
cefzil
cefprozil: structure given in first source. cefprozil : A semisynthetic, second-generation cephalosporin, with prop-1-enyl and (R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used to treat bronchitis as well as ear, skin and other bacterial infections.		1.9710
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		1.9710carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
ceftazidime
[no description available]		1.9710cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
aztreonam
[no description available]		1.9710beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610